P16Ink4a overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumors

Oncogene

Volumn 30, Issue 18, 2011, Pages 2087-2097

  Romagosa, C ^a   Simonetti, S ^b   Lopez Vicente L ^a   Mazo, A ^c   Lleonart, M E ^a   Castellvi, J ^a   Cajal, S Ramon Y ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

cancer; high grade; overexpression; p16Ink4a; senescence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

CANCER DIAGNOSIS; CANCER GRADING; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELLULAR DISTRIBUTION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE;

AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 79955636534     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.614     Document Type: Review

References (136)

1. Adachi Y, Lakka SS, Chandrasekar N, Yanamandra N, Gondi CS, Mohanam S et al. (2001). Down-regulation of integrin alpha(v) beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasmino-gen activator receptor (uPAR) and sense p16 genes. J Biol Chem 276: 47171-47177.
2. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742-13747. (Pubitemid 26424190)
3. Andujar P, Wang J, Descatha A, Galateau-Salle F, Abd-Alsamad I, Billon-Galland MA et al. (2010). p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 67: 23-30.
4. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A et al. (2008). Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 28: 2535-2539.
5. Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Saito T, Matsuura S et al. (2006). Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. J Neurooncol 77: 273-277. (Pubitemid 44404393)
6. Armes JE, Lourie R, de Silva M, Stamaratis G, Boyd A, Kumar B et al. (2005). Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24: 363-368. (Pubitemid 41368290)
7. Atkins KA, Arronte N, Darus CJ, Rice LW. (2008). The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 32: 98-102.
8. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT. (2010). The role of pRB, p16 and cyclin D1 in colonic carcino-genesis. Hepatogastroenterology 57: 251-256.
9. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF et al. (2006). Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103: 5947-5952.
10. Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P et al. (2002). CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236: 730-737. (Pubitemid 35403228)
11. Bastide K, Guilly MN, Bernaudin JF, Joubert C, Lectard B, Levalois C et al. (2009). Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung Cancer 63: 348-353.
12. Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, Travis WD et al. (2003). The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 34: 136-142. (Pubitemid 36258804)
13. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A et al. (2010). Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18: 135-146.
14. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665. (Pubitemid 41117262)
15. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C. (1999a). Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5: 243-250. (Pubitemid 29085175)
16. Brambilla E, Moro D, Gazzeri S, Brambilla C. (1999b). Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 188: 351-360. (Pubitemid 29327432)
17. Bringold F, Serrano M. (2000). Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 35: 317-329. (Pubitemid 30314689)
18. Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S. (2009). Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med 38: 104-108.
19. Calbo J, Marotta M, Cascallo M, Roig JM, Gelpi JL, Fueyo J et al. (2001). Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 8: 740-750. (Pubitemid 32983130)
20. Calbo J, Serna C, Garriga J, Grana X, Mazo A. (2004). The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity. Cell Death Differ 11: 1055-1065. (Pubitemid 39341631)
21. Campo-Trapero J, Cano-Sanchez J, Palacios-Sanchez B, Llamas-Martinez S, Lo Muzio L, Bascones-Martinez A. (2008). Cellular senescence in oral cancer and precancer and treatment implications: a review. Acta Oncol 47: 1464-1474.
22. Canepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF et al. (2007). INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59: 419-426. (Pubitemid 47123998)
23. Carnero A, Lleonart ME. (2010). Epigenetic mechanisms in senescence, immortalisation and cancer. Biol Rev Camb Philos Soc (doi:10.1111/j.1469-185X. 2010.00154.x).
24. Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ et al. (2010). (V600E)Braf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methyla-tion of p16(INK4a). EMBO Mol Med 2: 458-471.
25. Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS et al. (2008). Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 14: 6988-6995.
26. Chen JH, Ozanne SE, Hales CN. (2005). Heterogeneity in premature senescence by oxidative stress correlates with differential DNA damage during the cell cycle. DNA Repair (Amst) 4: 1140-1148. (Pubitemid 41316591)
27. Chien WW, Domenech C, Catallo R, Salles G, Ffrench M. (2010). S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53. Cell Cycle 9: 3286-3296.
28. Chim CS, Wong AS, Kwong YL. (2003). Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol 82: 738-742. (Pubitemid 38008841)
29. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK et al. (1997). Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-2057. (Pubitemid 27489132)
30. Collado M, Blasco MA, Serrano M. (2007). Cellular senescence in cancer and aging. Cell 130: 223-233. (Pubitemid 47081143)
31. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436: 642. (Pubitemid 41117258)
32. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM et al. (2006). A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10: 459-472. (Pubitemid 44872980)
33. Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz MI et al. (2009). Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 8: 1964-1973.
34. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y et al. (2000). p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119: 929-942.
35. Daniotti M, Ferrari A, Frigerio S, Casieri P, Miselli F, Zucca E et al. (2009). Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 129: 1759-1768.
36. Di Vinci A, Perdelli L, Banelli B, Salvi S, Casciano I, Gelvi I et al. (2005). p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114: 414-421. (Pubitemid 40279962)
37. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. (1998). Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 79: 71-75. (Pubitemid 28157730)
38. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M et al. (1998). Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668. (Pubitemid 28550055)
39. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, Kalogeropoulos N et al. (2004). Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) 'nuclear' cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 79: 5-10. (Pubitemid 38997099)
40. Fahraeus R, Lane DP. (1999). The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 18: 2106-2118. (Pubitemid 29179168)
41. Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A et al. (2010). Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 126: 1256-1262.
42. Fordyce C, Fessenden T, Pickering C, Jung J, Singla V, Berman H et al. (2010). DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res (Phila) 3: 190-201.
43. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE et al. (2002). Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160: 1573-1581. (Pubitemid 34525637)
44. Garcia V, Silva J, Dominguez G, Garcia JM, Pena C, Rodriguez R et al. (2004). Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. Mutat Res 554: 215-221. (Pubitemid 39140830)
45. Ghiorzo P, Pastorino L, Bonelli L, Cusano R, Nicora A, Zupo S et al. (2004). INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 15: 70-78. (Pubitemid 38139606)
46. Gil J, Peters G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667-677. (Pubitemid 44268212)
47. Gonzalez S, Serrano M. (2006). A new mechanism of inactivation of the INK4/ARF locus. Cell Cycle 5: 1382-1384. (Pubitemid 44159602)
48. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M et al. (1998). Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 153: 1749-1765. (Pubitemid 28550663)
49. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA et al. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95: 496-505. (Pubitemid 44232559)
50. Guenova M, Rassidakis GZ, Gorgoulis VG, Angelopoulou MK, Siakantaris MR, Kanavaros P et al. (1999). p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus. Mod Pathol 12: 1062-1071.
51. Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C et al. (2009). Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol 30: 267-270.
52. Gump J, Stokoe D, McCormick F. (2003). Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem 278: 6619-6622. (Pubitemid 36800647)
53. Gupta AK, Lee JH, Wilke WW, Quon H, Smith G, Maity A et al. (2009). Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 74: 928-933.
54. Haller F, Agaimy A, Cameron S, Beyer M, Gunawan B, Happel N et al. (2010). Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. Histopathology 56: 305-318.
55. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-867.
56. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S et al. (1999). Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59: 3783-3789. (Pubitemid 29381887)
57. Hayflick L. (1965). The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614-636.
58. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE et al. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530.
59. Herschkowitz JI, He X, Fan C, Perou CM. (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10: R75.
60. Hilliard NJ, Krahl D, Sellheyer K. (2009). p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol 36: 753-759.
61. Hiroyasu M, Ozeki M, Kohda H, Echizenya M, Tanaka T, Hiai H et al. (2002). Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol 160: 419-424. (Pubitemid 34160318)
62. Horree N, van Diest PJ, Sie-Go DM, Heintz AP. (2007). The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 38: 1232-1238. (Pubitemid 47058161)
63. Hruban RH, Klein AP, Eshleman JR, Axilbund JE, Goggins M. (2007). Familial pancreatic cancer: from genes to improved patient care. Expert Rev Gastroenterol Hepatol 1: 81-88.
64. Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L et al. (1993). Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 13: 953-960. (Pubitemid 23040261)
65. 0 CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas. BMC Cancer 7: 47.
66. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R et al. (2001). The invasion front of human colorectal adenocarci-nomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 159: 1613-1617. (Pubitemid 33062503)
67. Kannengiesser C, Brookes S, del Arroyo AG, Pham D, Bombled J, Barrois M et al. (2009). Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat 30: 564-574.
68. Kataoka M, Wiehle S, Spitz F, Schumacher G, Roth JA, Cristiano RJ. (2000). Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene 19: 1589-1595. (Pubitemid 30175681)
69. Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, Roth JA et al. (2002). Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 21: 2108-2113. (Pubitemid 34270900)
70. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J et al. (2010). Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102: 627-637.
71. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S et al. (2009). Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15: 81-90.
72. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. (1999). Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 155: 1855-1860.
73. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L et al. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114: 1299-1307. (Pubitemid 40385301)
74. Ksiazek K, Piwocka K, Brzezinska A, Sikora E, Zabel M, Breborowicz A et al. (2006). Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16INK4a-mediated premature senescence. J Appl Physiol 100: 988-995. (Pubitemid 43671556)
75. Lam AK, Ong K, Giv MJ, Ho YH. (2008). p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 40: 580-585.
76. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. (2009). Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1992-1998.
77. Li L, Lu Y. (2010). Inhibition of hypoxia-induced cell motility by p16 in MDA-MB-231 breast cancer cells. J Cancer 1: 126-135.
78. Lleonart ME, Artero-Castro A, Kondoh H. (2009). Senescence induction; a possible cancer therapy. Mol Cancer 8: 3.
79. Lobo GP, Waite KA, Planchon SM, Romigh T, Houghton JA, Eng C. (2008). ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet 17: 2877-2885.
80. Lopez-Vicente L, Armengol G, Pons B, Coch L, Argelaguet E, Lleonart M et al. (2009). Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res 15: 4546-4553.
81. Lynch BC, Lathrop SL, Ye D, Ma TY, Cerilli LA. (2008). Expression of the p16(INK4a) gene product in premalignant and malignant epithelial lesions of the gallbladder. Ann Diagn Pathol 12: 161-164. (Pubitemid 351672097)
82. Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. (2008). Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer 7: 331-337.
83. Marchan S, Perez-Torras S, Vidal A, Adan J, Mitjans F, Carbo N et al. (2010). Dual effects of beta3 integrin subunit expression on human pancreatic cancer models. Anal Cell Pathol (Amst) 33: 191-205.
84. Marsh KL, Varley JM. (1998). Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohis-tochemistry. Br J Cancer 77: 1460-1468. (Pubitemid 28190746)
85. Martin A, Baran-Marzak F, El Mansouri S, Legendre C, Leblond V, Charlotte F et al. (2000). Expression of p16/INK4a in post-transplantation lymphoproliferative disorders. Am J Pathol 156: 1573-1579. (Pubitemid 30646697)
86. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescencelike cell cycle arrest of human naevi. Nature 436: 720-724. (Pubitemid 41117276)
87. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T. (2001). Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70. (Pubitemid 32703389)
88. Minami R, Muta K, Umemura T, Motomura S, Abe Y, Nishimura J et al. (2003). p16(INK4a) induces differentiation and apoptosis in erythroid lineage cells. Exp Hematol 31: 355-362. (Pubitemid 36579361)
89. Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK. (2001). In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 7: 1765-1772. (Pubitemid 32708647)
90. Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A et al. (2007). BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 6: 453-461. (Pubitemid 47622260)
91. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M et al. (2001a). Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84: 253-262. (Pubitemid 32113454)
92. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR et al. (2001b). Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439: 798-802. (Pubitemid 33141325)
93. Mulvany NJ, Allen DG, Wilson SM. (2008). Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 40: 335-344. (Pubitemid 351630885)
94. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. (1989). Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099-4105. (Pubitemid 20066852)
95. Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG. (2003). Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 163: 477-491. (Pubitemid 36909411)
96. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. (1999). Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155: 1879-1884.
97. Nilsson K, Landberg G. (2006). Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer 118: 1120-1125. (Pubitemid 43185597)
98. Nilsson K, Svensson S, Landberg G. (2004). Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod Pathol 17: 1464-1474. (Pubitemid 39627072)
99. O'Neill CJ, McBride HA, Connolly LE, McCluggage WG. (2007). Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50: 851-858. (Pubitemid 46850073)
100. Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, Wolvetang E et al. (2003). Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 162: 173-183. (Pubitemid 36928832)
101. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA et al. (2007). CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 127: 1234-1243. (Pubitemid 46625153)
102. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R. (2000). Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol 157: 1947-1953.
103. Passegue E, Wagner EF. (2000). JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 19: 2969-2979. (Pubitemid 30386768)
104. Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL et al. (2008). p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One 3: e3809.
105. Pei XH, Xiong Y. (2005). Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24: 2787-2795. (Pubitemid 40638090)
106. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A et al. (2003). p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 9: 4132-4138. (Pubitemid 37204030)
107. Quereda V, Martinalbo J, Dubus P, Carnero A, Malumbres M. (2007). Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene 26: 7665-7674. (Pubitemid 350224221)
108. Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Durr P et al. (2006). p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 5: 379-389. (Pubitemid 44322534)
109. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E et al. (2008). Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123: 2626-2631.
110. Romagosa C, Simonetti S, Serrano C, Lopez-Vicente L, Esquinas M, Moline T et al. (2009). Senescence markers in Schwannomas. Virchows Archiv 455: 372.
111. Ruas M, Gregory F, Jones R, Poolman R, Starborg M, Rowe J et al. (2007). CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms. Mol Cell Biol 27: 4273-4282. (Pubitemid 46906552)
112. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. (2003). CDKN2A point mutations D153spl(c.457G4T) and IVS2+1G4T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 22: 4444-4448. (Pubitemid 36897975)
113. Sabah M, Cummins R, Leader M, Kay E. (2006). Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. Appl Immunohistochem Mol Morphol 14: 97-102.
114. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L et al. (1999). Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94: 765-772. (Pubitemid 29323891)
115. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346. (Pubitemid 34606876)
116. Schmitt E, Paquet C, Beauchemin M, Bertrand R. (2007). DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B 8: 377-397.
117. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P et al. (2005). Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11: 638-645. (Pubitemid 40116890)
118. Schwabe M, Lubbert M. (2007). Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 8: 382-387. (Pubitemid 350268197)
119. Schwartz B, Avivi-Green C, Polak-Charcon S. (1998). Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Mol Cell Biochem 188: 21-30. (Pubitemid 28493314)
120. Serrano C, Simonetti S, Hernandez J, Valverde C, Carles J, Baguer S et al. (2010). BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors. J Clin Oncology 28 (Suppl): abstract 10043.
121. Serrano M. (1997). The tumor suppressor protein p16INK4a. Exp Cell Res 237: 7-13.
122. Serrano M. (2007). Cancer regression by senescence. N Engl J Med 356: 1996-1997.
123. Shen WW, Wu J, Cai L, Liu BY, Gao Y, Chen GQ et al. (2007). Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma. Neoplasia 9: 812-819. (Pubitemid 47623421)
124. Souza-Rodrigues E, Estanyol JM, Friedrich-Heineken E, Olmedo E, Vera J, Canela N et al. (2007). Proteomic analysis of p16ink4a-binding proteins. Proteomics 7: 4102-4111.
125. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Loberg EM, Isaksen V et al. (2008). Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 21: 46-53.
126. Svensson S, Nilsson K, Ringberg A, Landberg G. (2003). Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 63: 1737-1742. (Pubitemid 36460829)
127. Tanaka T, Iwasa Y, Kondo S, Hiai H, Toyokuni S. (1999). High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 18: 3793-3797. (Pubitemid 29338514)
128. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153. (Pubitemid 26010393)
129. Wang Y, Zhang Z, Lubet R, You M. (2005). Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 24: 3042-3049. (Pubitemid 40675535)
130. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF et al. (2000). p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 14: 2358-2365.
131. Wu J, Xue L, Weng M, Sun Y, Zhang Z, Wang W et al. (2007). Sp1 is essential for p16 expression in human diploid fibroblasts during senescence. PLoS One 2: e164.
132. Yogev O, Anzi S, Inoue K, Shaulian E. (2006). Induction of transcriptionally active Jun proteins regulates drug-induced senescence. J Biol Chem 281: 34475-34483. (Pubitemid 46036655)
133. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. (2006). Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol 19: 1339-1343. (Pubitemid 44423081)
134. Zhao P, Mao X, Talbot IC. (2006). Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol 12: 6391-6396. (Pubitemid 44712426)
135. Zhu D, Xu G, Ghandhi S, Hubbard K. (2002). Modulation of the expression of p16INK4a and p14ARF by hnRNP A1 and A2 RNA binding proteins: implications for cellular senescence. J Cell Physiol 193: 19-25. (Pubitemid 34969124)
136. Zindy F, Quelle DE, Roussel MF, Sherr CJ. (1997). Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211. (Pubitemid 27344559)